A Closer Look at NHS England’s AF-related Stroke Prevention Demonstrator Sites

NHS England Logo

A project aimed at preventing fatal strokes in those with Atrial Fibrillation is now underway with 23 demonstrator CCGs across England receiving part of the £9 Million put forward by NHS England.

The funding was allocated by the NHS to pay for virtual clinics in which Pharmacists can assist GPs in the detection and management of patients with Atrial Fibrillation (AF).

Who are the Demonstrator Sites and how were they chosen?

The following 23 CCGs have been chosen and have agreed to act as demonstrators sites for the NHS England funded AF programme. These CCGs have been targeted due to high areas of deprivation (using data from the Indices of Multiple Deprivation 2015) and low prevalence. These CCGs will have high numbers of patients who have been diagnosed with AF who are not being treated and managed optimally.

The CCGs taking part are:

  • NHS Barnet CCG
  • NHS Bradford City CCG
  • NHS Brent CCG
  • NHS Camden CCG
  • NHS Chorley and South Ribble CCG
  • NHS Croydon CCG
  • NHS Enfield CCG
  • NHS Great Yarmouth and Waveney CCG
  • NHS Greenwich CCG
  • NHS Haringey CCG
  • NHS Harrow CCG
  • NHS Isle of Wight CCG
  • NHS Islington CCG
  • NHS Kingston CCG
  • NHS Leeds CCG
  • NHS Morecambe Bay CCG
  • NHS North Cumbria CCG
  • NHS North Tyneside CCG
  • NHS Northumberland CCG
  • NHS Portsmouth CCG
  • NHS South Kent Coast CCG
  • NHS Thanet CCG
  • NHS West Lancashire CCG

What is the range of AF detection rates?

Currently there are no demonstrator sites meeting the aspirational 2029 85% detection rate, the detection rate ranges from 49.1% to 84.1%.

As a result there are 15,950 AF patients across all demonstrator sites who need to be detected to meet the aspirational 2029 85% detection target.

How many high-risk AF patients need anticoagulating?

Even at the current low prevalence, there are still 4,067 AF high-risk patients across all demonstrator sites who need to be anticoagulated to reach the minimum current 84% anticoagulation target rate.

Once detection rates increase and more patients are identified, this number is likely to increase significantly.

Oberoi Consulting’s Stroke Prevention in AF (SPAF) & Case Finding service is perfectly aligned to support Pharmacists in the demonstrator sites to efficiently identify and target patients of highest risk whilst continually being able to monitor the impact of their work along with perfecting treatment of Direct Oral Anti-Coagulants (DOACs) and Warfarin.

Demonstrator sites, Thanet CCG and South Kent Coast CCG have signed up to the service and Oberoi SPAF & Case Finding has since been deployed in pilot practices.

Re-audit results are showing the clear impact of the work. In one practice alone in Thanet CCG the detection rate of AF patients has increased from 83.5% to 93%. An additional 45 high risk AF patients have also now been anti-coagulated and more importantly patients prevented from an AF related stroke.

Oberoi SPAF and Case Finding Logo
Click image to visit the Oberoi SPAF & Case Finding page

Oberoi SPAF & Case Finding service can support demonstrator sites of the NHS England AF project and CCGs looking to improve AF outcomes through:

  • Searches integrated into GP clinical systems which support virtual clinics
  • Prompts and alerts to support opportunistic diagnosis and management
  • Case finding prompts linked to templates
  • Templates to assist management and recall of patients for review
  • Practice baseline and re-audit reports - highlighting key detect, protect and perfect data
  • Benchmarking reports across participating practice
  • E-portal for users to view reports and educational materials
  • Lead 1 ECG training

Oberoi Consulting have also developed an RCGP accredited workshop ‘The Modern Management of AF’; aimed at upskilling Pharmacists and GPs on AF.

To find out more, please call 01332 224 251 or email admin@oberoi-consulting.com